knowledge -WSS

knowledge

author：comprehensive 2025-09-30 23:07:43 - browse：69

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons.

The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients living with MLD today. But when given in time, it appears to be near-curative, allowing some children to grow up and attend school with unaffected peers.

Lenmeldy is already marketed in Europe, under the name Libmeldy, and has helped a handful of patients in the U.S. who were treated under compassionate use, as their doctors feared they didn’t have time to wait for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

hotspot

WSS

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

My yearlong odyssey to get my son’s ADHD medication covered

ReNAgade cuts staff seven months after raising $300 million

Prior authorization will have to move faster under new Biden rule

Research misconduct: Proposed new rules face resistance

As biotech industry slumps, bioscience job market is upside down

explore

knowledge

Wikipedia

Continuity nursing helped my family in our darkest PICU moments

EU regulator recommends expanding Mounjaro approval to obesity

Medical leaders decry Supreme Court decision on affirmative action

eGenesis tests gene

Continuity nursing helped my family in our darkest PICU moments

Francis Collins on trust in science and how Covid communications failed

New air purifier tech could be key to improving indoor air quality

New brain studies show LSD's effects on the brain in full color

Medicare details structure of new drug price negotiation program

Flagship Pioneering launches a new biotech in two countries

leisure time

U.K. Biobank has 500,000 peoples' genome sequences available

What to do when lifesaving products contribute to climate change

BIO selects John Crowley as new CEO

NIH director takes cautious approach to Biden drug pricing priority

Prior authorization will have to move faster under new Biden rule

30 years of 'Listening to Prozac'

leisure time

focus

hotspot

hotspot